NCT02821182View on ClinicalTrials.gov

A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

September 9, 2018

Study Completion Date

December 31, 2019

Conditions
Melanoma
Interventions
RADIATION

stereotactic body radiotherapy

"In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated \>48h and \<96h."

Trial Locations (1)

9000

University Hospital Ghent, Ghent

All Listed Sponsors
collaborator

GZA Ziekenhuizen Campus Sint-Augustinus

OTHER

lead

University Hospital, Ghent

OTHER

NCT02821182 - A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma. | Biotech Hunter | Biotech Hunter